Common stock, par value $0.001 per share
- Symbol
- TDOC
- Exchange
- NYSE
- Classification
- COMMON
- Status
- Current
Current Report · Items 5.02, 7.01, 9.01 · 8-K
Teladoc Health, Inc.
TDOCNYSEEQUITYCurrent
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD Disclosure
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Effective August 3, 2026, the Board of Directors (the “Board”) of Teladoc Health, Inc. (the “Company”) increased the number of directors on the Board to ten and appointed Mark V. Anquillare as a director of the Company. Mr.…
Press release in this filing
Teladoc Health Appoints Financial Executive Mark Anquillare to Its Board of Directors →Recent company filings
- 10-Q filingOct 29, 2026
- Results of Operations and Financial ConditionOct 28, 2026
- SCHEDULE 13G - filed by DIMENSIONAL FUND ADVISORS LP regarding Teladoc Health, Inc.Oct 8, 2026
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsSep 25, 2026
- 4 filingSep 14, 2026
Registered securities in this filing
Teladoc Health, Inc. · 8-K · Filed 2026-08-03
Disclosure sections
Item 5.02Item 5.02 - Departure/Election of Directors
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Effective August 3, 2026, the Board of Directors (the “Board”) of Teladoc Health, Inc. (the “Company”) increased the number of directors on the Board to ten and appointed Mark V. Anquillare as a director of the Company. Mr. Anquillare was additionally appointed to each of the audit committee and the compensation committee of the Board. The Board has determined that Mr. Anquillare is an independent director within the meaning of the New York Stock Exchange listing standards and is an “audit committee financial expert” under Securities and Exchange Commission (the “SEC”) and New York Stock Exchange rules.
There are no arrangements or understandings between Mr. Anquillare and any other person pursuant to which he was selected as a director. There are no transactions involving the Company and Mr. Anquillare that the Company would be required to report pursuant to Item 404(a) of Regulation S-K.
Mr. Anquillare will have the same director indemnification arrangement as do the Company’s other directors appointed since October 2020, the form of agreement for which was filed with the SEC on March 1, 2021 as Exhibit 10.2 to the Company’s Annual Report on Form 10-K. Mr. Anquillare will be eligible to participate in the compensation arrangements and programs that are established for the Company’s non-employee directors, as in effect from time to time, which are described in the Company’s Proxy Statement on Schedule 14A filed with the SEC on April 7, 2026.
Item 7.01Item 7.01 - Regulation FD Disclosure
Item 7.01
Regulation FD.
On August 3, 2026, the Company issued a press release regarding the matter discussed in Item 5.02 of this Current Report. A copy of the press release is furnished herewith as Exhibit 99.1.
The information furnished under this Item 7.01 of this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.